TD Private Client Wealth LLC Reduces Stock Position in Sanofi (NASDAQ:SNY)

TD Private Client Wealth LLC reduced its holdings in Sanofi (NASDAQ:SNY) by 8.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 93,033 shares of the company’s stock after selling 8,763 shares during the period. TD Private Client Wealth LLC’s holdings in Sanofi were worth $4,487,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SNY. Synergy Asset Management LLC purchased a new position in shares of Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its stake in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi during the 4th quarter worth about $31,000. Sunbelt Securities Inc. boosted its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. Finally, Sierra Ocean LLC bought a new stake in Sanofi during the 4th quarter valued at about $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Down 1.5 %

NASDAQ:SNY opened at $56.90 on Friday. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market cap of $144.40 billion, a P/E ratio of 22.85, a P/E/G ratio of 1.01 and a beta of 0.58. The firm has a 50-day simple moving average of $54.55 and a 200-day simple moving average of $52.93.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 price objective for the company. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.